Litmus Health’s profile of the wearables market names the top 15 devices today available to researchers incorporating real-life data into studies and trials – with a focus on data quality and transparency.
Biovation expands its technology portfolio with all-encompassing tableting equipment to grow its production capacity and change specifications ‘on the fly’.
The Asia-Pacific CRO Novotech has grown its operations in South Korea, a market that has seen greater interest from North American and European companies, says exec.
The US Court of Appeals for the Federal Circuit removed the injunction against Dr. Reddy’s, which prevented the company from selling its Suboxone generic.
The colour of a capsule can play an important role in the safety of a product and provide consumers with intuitive information for dosage, according to Nicolas Madit of Lonza.
ABL named a successor to its previous CEO, Syneos has two new hires, and BTS Research appointed a VP to push its growth model. These, among other people on the move this month.
If the industry wants to maintain control of manufacturing operations, it has to adopt digital technologies or face being ousted by Amazon, suggested GSK’s Pharma 4.0 director.
Catalent’s existing clinical packaging facility in Shanghai is nearing the end of its expansion, ready to meet the needs of the growing Asia-Pacific region.
Novartis has announced plans to move its UK headquarters to an ‘emerging life sciences cluster’ in West London, 50 minutes’ drive from its current location in Surrey.
PRA Health Sciences has launched a new site network focused on improving pediatric clinical development and access to novel medicines in this special patient population.
Evotec and Immuneering are combining iPSC and AI technologies through a research collaboration to discover novel small molecules for rare hereditary metabolic diseases.
GW Pharma has told investors its capacity is “more than sufficient” to meet launch requirements in Europe next year, where the firm’s CBD medicine Epidiolex is under review.
The new recommendations look to provide a more efficient and effective means of qualifying clinical trial investigators – to help teams ‘conduct better, more efficient clinical trials,’ says CTTI exec.
Cyclica, a Bayer G4A company, will work with Bayer to advance drug discovery. The collaboration will involve looking further into polypharmacological profiles of small molecules.
The industry must be “relentless” in driving the adoption of new advances in technology, says Janssen, which has shifted from doing things for patients and investigators, to doing things with them.
WHO recently assessed Biopharma Services, which demonstrated compliance across multiple regulatory and organizational guidelines – opening the doors to conduct more work with the WHO foundations.
Fusion Antibodies signed an agreement with Analytics Engines to bring machine learning and AI to its humanization platform in an aim to bolster product quality and manufacturability.
QPS has expanded its Phase I clinical trial capabilities by more than 20% and doubled its lab space, which will allow the CRO to accommodate ‘exponentially more sponsors’ as demand continues to increase.
The Indian firm is relocating manufacturing operations in New Jersey, from its Cranbury facility to New Brunswick, in an effort to “improve cost efficiencies” across the US.
Pharma companies have improved or maintained standards for effective drug recalls, product packaging and managing supply in LMICs, according to the report.
World Courier has made a multimillion-dollar investment in its supply chain technology to help meet the expanding needs of the pharmaceutical industry.
Rather than limit health care data collection, the industry should focus on ensuring those data sets are used ‘in the most appropriate way,’ according to Health iQ chief commercial officer.
Takeda’s aim to acquire Shire for $62bn received a boost after regulators vote positively to approve the transaction following the divestment of Shire’s IBD drug.
Moving forward, China will take a more integral role in global drug development, following several regulatory changes designed to accelerate innovation.
Blockchain provides real-time visibility into the entire clinical trial supply chain and has the potential to solve several of the industry’s biggest challenges.
